SEC Company Response from Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Aug 17, 2017
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Aug. 17, 2017 · CIK: 0001359931 · Accession: 0001171843-17-005157
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219676
Letter
Proteon Therapeutics, Inc.
200 West Street
Waltham, MA 02145
(781) 890-0102
August 17, 2017
Via EDGAR and FedEx
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Suzanne Hayes
RE: Proteon Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-219676
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), be accelerated to 4:30 p.m. Eastern Time, on August 21, 2017 or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time. In the event you are orally notified, you will be contacted either by me, or Julio E. Vega of Morgan, Lewis & Bockius LLP.
The Company hereby acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions regarding this request, please do not hesitate to contact Julio E. Vega of Morgan, Lewis & Bockius LLP, counsel to the Company, at (617) 951-8901.
Please contact Julio E. Vega as soon as the Registration Statement has been declared effective.
Sincerely,
PROTEON THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Proteon Therapeutics, Inc.
200 West Street
Waltham, MA 02145
(781) 890-0102
August 17, 2017
Via EDGAR and FedEx
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Suzanne Hayes
RE: Proteon Therapeutics, Inc.
Registration Statement
on Form S-3
File No. 333-219676
Ladies and Gentlemen:
Pursuant to Rule 461
of the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the “Company”),
hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-3, as amended (the
“Registration Statement”), be accelerated to 4:30 p.m. Eastern Time, on August 21, 2017 or as soon as
practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time.
In the event you are orally notified, you will be contacted either by me, or Julio E. Vega of Morgan, Lewis & Bockius LLP.
The Company hereby
acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff
(the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any
questions regarding this request, please do not hesitate to contact Julio E. Vega of Morgan, Lewis & Bockius LLP, counsel to
the Company, at (617) 951-8901.
Please contact Julio
E. Vega as soon as the Registration Statement has been declared effective.
Sincerely,
PROTEON THERAPEUTICS, INC.
/s/ George A. Eldridge
Name:
George A. Eldridge
Title:
Senior
Vice President, Chief Financial Officer, Treasurer and Assistant Secretary
cc: Irene Paik, U.S. Securities and Exchange Commission
Julio E. Vega, Morgan,
Lewis & Bockius LLP